Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy
Launched by PEKING UNIVERSITY FIRST HOSPITAL · Oct 11, 2022
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a program called the Enhanced Recovery After Surgery (ERAS) Pathway, which aims to help men recover faster after undergoing robot-assisted laparoscopic radical prostatectomy (RARP) surgery for prostate cancer. The ERAS Pathway includes evidence-based practices designed to reduce stress on the body during surgery and help patients get back on their feet more quickly. Researchers want to see how this approach impacts recovery time and overall outcomes for patients after their surgery.
To be eligible for this trial, participants must be men aged 60 to 89 who are scheduled to have RARP surgery for prostate cancer. Those with certain health conditions or who need additional surgeries at the same time will not be able to participate. If you join the trial, you'll receive care based on the ERAS Pathway, which may include specific exercises and support before and after your surgery. This study is currently not recruiting participants, but it aims to provide valuable insights that could improve recovery for many men facing prostate cancer treatment in the future.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Aged 60 years or over but below 90 years.
- • Scheduled to undergo robot-assisted laparoscopic radical prostatectomy (RARP) for prostate cancer.
- • Agree to participate in this study and give written informed consent.
- Exclusion Criteria:
- • Scheduled to undergo combined surgery, including RARP combined with pelvic lymph node dissection or other procedures.
- • American Society of Anesthesiologists (ASA) physical classification ≥IV.
- • Inability to receive preoperative aerobic exercise because of severe cardiovascular disease, motor system diseases (arthritis, lumbar vertebrae disease), or central nervous system diseases (epilepsy, parkinsonism).
- • Inability to communicate in the preoperative period because of profound dementia, deafness, or language barriers.
- • History of schizophrenia, anxiety or depressive disorders, or other mental disorders.
About Peking University First Hospital
Peking University First Hospital is a leading medical institution in China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive expertise in various medical fields to conduct rigorous studies aimed at improving patient outcomes and contributing to global medical knowledge. With a multidisciplinary team of skilled researchers and clinicians, Peking University First Hospital is dedicated to the ethical conduct of clinical research, ensuring the highest standards of safety and efficacy in its trials. The institution plays a vital role in translating scientific discoveries into effective treatments, thereby enhancing the quality of care for patients both locally and worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Dong-Xin Wang, MD, PhD
Principal Investigator
Peking University First Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials